Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-06-03 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
百克生物首次公开发行股票并在科创板上市招股意向书
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for the initial public offering (IPO) and listing of Changchun BCHT Biotechnology Co. on the Shanghai Stock Exchange STAR Market (科创板). It includes extensive information about the company's business, risk factors, financial data, governance, and other disclosures typical of an IPO prospectus. The document is titled as a 招股意向书 (prospectus or offering document) and contains detailed financial and operational information, including audited and reviewed financial statements, risk disclosures, and governance details. This type of document is not an earnings release, call transcript, or a simple announcement but a comprehensive offering document related to capital raising and listing. According to the filing definitions, such documents related to fundraising and capital structure changes fall under Capital/Financing Update (CAP). It is not an Annual Report (10-K), Interim Report (IR), or Audit Report (AR). It is also not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive financial and business information, not just an announcement. Therefore, the best classification is Capital/Financing Update (CAP).
2021-06-03 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.